Logo image
Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy
Journal article   Peer reviewed

Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy

Sarah K Nabukera, Paul A Romitti, Kimberly A Campbell, F John Meaney, Kristin M Caspers, Katherine D Mathews, Stacey M Hockett Sherlock, Soman Puzhankara, Christopher Cunniff, Charlotte M Druschel, …
Journal of child neurology, Vol.27(6), pp.734-740
06/2012
DOI: 10.1177/0883073811426501
PMCID: PMC5882202
PMID: 22156783
url
http://doi.org/10.1177/0883073811426501View
Open Access

Abstract

Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy was examined using interview reports from caregivers enrolled in the population-based Muscular Dystrophy Surveillance, Tracking, and Research Network. Of the 200 caregivers interviewed, 160 (80%) reported "ever" using complementary and alternative medicine for their affected children. Mind-body medicine (61.5%) was most frequently used, followed by biologically based practices (48.0%), manipulative and body-based practices (29.0%), and whole medical systems (8.5%). Caregivers reporting use of whole medical systems had higher education and income levels compared with nonusers; affected males had shorter disease duration. Caregivers reporting use of mind-body medicine, excluding aquatherapy, had higher education level compared with nonusers. Overall, complementary and alternative medicine use was high; disease duration, education, and income levels influenced use. These findings have implications for developing clinical care protocols and monitoring possible interactions between complementary and alternative medicine and conventional medical therapies.
Caregivers Humans Middle Aged Complementary Therapies - trends Male Muscular Dystrophy, Duchenne - epidemiology Complementary Therapies - methods Adult Complementary Therapies - statistics & numerical data Retrospective Studies Interview, Psychological Muscular Dystrophy, Duchenne - therapy Population Surveillance

Details

Metrics

Logo image